These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 19744248

  • 21. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
    Mazzone T.
    Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
    [Abstract] [Full Text] [Related]

  • 22. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ.
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [Abstract] [Full Text] [Related]

  • 23. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [Abstract] [Full Text] [Related]

  • 24. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group.
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [Abstract] [Full Text] [Related]

  • 25. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators.
    J Am Coll Cardiol; 2007 May 01; 49(17):1772-80. PubMed ID: 17466227
    [Abstract] [Full Text] [Related]

  • 26. Prevention of coronary heart disease in type 2 diabetes.
    Mykkänen L.
    Int J Clin Pract Suppl; 2000 Oct 01; (113):40-5. PubMed ID: 11965831
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Outcomes and lessons from the PROactive study.
    Scheen AJ.
    Diabetes Res Clin Pract; 2012 Nov 01; 98(2):175-86. PubMed ID: 23020930
    [Abstract] [Full Text] [Related]

  • 31. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC, Haffner SM.
    JAMA; 2006 Dec 06; 296(21):2572-81. PubMed ID: 17101640
    [Abstract] [Full Text] [Related]

  • 32. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M, GLAC Study Group.
    Diabet Med; 2004 Aug 06; 21(8):859-66. PubMed ID: 15270789
    [Abstract] [Full Text] [Related]

  • 33. Pioglitazone and mechanisms of CV protection.
    Erdmann E, Wilcox R.
    QJM; 2010 Apr 06; 103(4):213-28. PubMed ID: 19955228
    [Abstract] [Full Text] [Related]

  • 34. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
    Erdmann E, Spanheimer R, Charbonnel B, PROactive Study Investigators.
    J Diabetes; 2010 Sep 06; 2(3):212-20. PubMed ID: 20923486
    [Abstract] [Full Text] [Related]

  • 35. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE.
    JAMA; 2007 Sep 12; 298(10):1180-8. PubMed ID: 17848652
    [Abstract] [Full Text] [Related]

  • 36. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Miranda VP, Rodrigues MJ, Gonçalves FR, Nunes JP.
    Rev Port Cardiol; 2009 Oct 12; 28(10):1099-119. PubMed ID: 20058777
    [Abstract] [Full Text] [Related]

  • 37. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
    Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, PROactive Investigators.
    Diabetes Care; 2007 Nov 12; 30(11):2773-8. PubMed ID: 17666462
    [Abstract] [Full Text] [Related]

  • 38. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
    Holleman F, Gerdes VE, de Vries JH, Hoekstra JB.
    Ned Tijdschr Geneeskd; 2006 Feb 18; 150(7):358-60. PubMed ID: 16523797
    [Abstract] [Full Text] [Related]

  • 39. [Evidences demonstrating the effects of prevention of major adverse cardiovascular events and anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive study and PERISCOPE study].
    Kawamori R.
    Nihon Rinsho; 2011 Jan 18; 69 Suppl 1():671-7. PubMed ID: 21766679
    [No Abstract] [Full Text] [Related]

  • 40. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
    Fisher M.
    Int J Clin Pract; 2009 Sep 18; 63(9):1354-68. PubMed ID: 19691621
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.